Medpage Today on MSN3d
No Benefit for PD-1 Inhibitors in Certain Gastroesophageal Cancers, FDA Panel SaysThe Oncologic Drugs Advisory Committee (ODAC) decided 10-2 with one abstention that PD-1 inhibitors do not have a favorable ...
The days of broad stomach cancer labels for PD-1 inhibitors appear to be numbered. | The days of broad stomach cancer labels ...
After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or ...
A new series of proteolytic targeting chimeras (PROTACs) was designed by Zhejiang University of Technology scientists based ...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a ...
If approved, the potential restrictions would impact Merck’s Keytruda and Bristol Myers Squibb’s Opdivo, which are marketed ...
The FDA's advisory committee is set to evaluate the use of PD-1 inhibitors in gastric cancer patients, focusing on the risks ...
"If patients with low or no PD-L1 expression are not expected to benefit based on the available data, then administering anti ...
Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...
The FDA’s Oncologic Drug Advisory Committee voted against the use of checkpoint inhibitors in first-line advanced gastric ...
Having said that, it is because this company made a move about a month ago to receive ex-China development and commercial rights to ImmuneOnco's PD-L1/VEGF bispecific antibody known as IMM2510 ...
The results showed that in patients with known CLDN18.2 and PD-L1 status, the median progression-free survival (mPFS) reached ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback